Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Q&A: Philip Greenberg on T Cells, IO's Future

    Cancer Discovery
    |July 10, 2023
    PubMed
    Summary

    Philip Greenberg, MD, leads the American Association for Cancer Research, focusing on public communication and T-cell receptor therapies. He also discussed the future of immuno-oncology research.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same journal

    Brain Network Connectivity Predicts Survival in Diffuse Midline Glioma.

    Cancer discovery·2026
    Same journal

    First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts.

    Cancer discovery·2026
    Same journal

    CDK8 Inhibition Releases the Muscle Differentiation Block in Fusion-driven Alveolar Rhabdomyosarcoma.

    Cancer discovery·2026
    Same journal

    CDK8 inhibition induces Mediator trapping and impairment of the EWSR1::FLI1 transcriptional program in Ewing sarcoma.

    Cancer discovery·2026
    Same journal

    SEZ6-Targeted ADC Shows Preliminary Efficacy in Small Cell Lung Cancer.

    Cancer discovery·2026
    Same journal

    Nonprofit Acquires Abandoned Leukemia Drug Supply.

    Cancer discovery·2026

    Area of Science:

    • Oncology
    • Immunology
    • Scientific Communication

    Background:

    • Philip Greenberg, MD, began his term as president of the American Association for Cancer Research (AACR) in April 2023.
    • The interview covers key priorities for his tenure and his perspectives on cancer research.

    Purpose of the Study:

    • To outline the strategic priorities for the American Association for Cancer Research under new leadership.
    • To discuss advancements and future directions in T-cell receptor therapies and immuno-oncology.

    Main Methods:

    • Interview-based discussion of leadership priorities.
    • Overview of current research in T-cell receptor therapies.
    • Expert commentary on the future of immuno-oncology.

    Main Results:

    • Key priorities include enhancing scientists' public communication skills.
    • T-cell receptor therapies represent a significant area of ongoing research.
    • The next decade is anticipated to bring substantial progress in immuno-oncology.

    Conclusions:

    • Effective public communication is crucial for scientific advancement.
    • T-cell receptor therapies hold promise for cancer treatment.
    • Immuno-oncology is poised for significant growth and innovation.

    Related Experiment Videos